Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report

RATIONALE: Significant concerns about the adverse effects following chimeric antigen receptor T cell (CAR-T) therapy are still remained including cytokine release syndrome (CRS). In rare circumstances, CRS may be refractory to tocilizumab and/or corticosteroids, a new treatment is needed for the man...

Descripción completa

Detalles Bibliográficos
Autores principales: Zi, Fu Ming, Ye, Long Long, Zheng, Ji Fu, Cheng, Jing, Wang, Qing Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133263/
https://www.ncbi.nlm.nih.gov/pubmed/34106613
http://dx.doi.org/10.1097/MD.0000000000025786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133263/
https://www.ncbi.nlm.nih.gov/pubmed/34106613
http://dx.doi.org/10.1097/MD.0000000000025786

Ejemplares similares